(1 - 38 from 66
)
WellPoint CEO's management criticized
www.fiercehealthpayer.com
[FierceHealthPayer] - "It would be unusual to remove a CEO in the middle of a major acquisition," Erik Gordon a University of Michigan business professor, told Bloomberg. Ana Gupte, a Sanford C. Bernstein & Co. analyst, agreed. Although investors "are questioning her
Bristol-Myers suspends hepatitis C treatment study
www.huffingtonpost.com
[Huffington Post] - Analyst Erik Gordon, a professor at the University of Michigan's Ross School of Business, said the study suspension makes the Inhibitex acquisition look like a mistake for Bristol-Myers. Hepatitis C is a virus that can lead to life-threatening liver
Glaxo and Pfizer create new HIV drug company - Boston.com
archive.boston.com
Analyst and University of Michigan business professor Erik Gordon said that cost-cutting is the driver behind forming a new company rather than doing a typical co-development deal.
sorted by relevance / date